MariTide: The Next Big Disruptor in GLP-1 Weight-Loss Drugs
Friday, 17 May 2024, 12:24
MariTide: The Game-Changing GLP-1 Drug Ready to Shake Up the Healthcare Market
Could Amgen be the next stock to soar due to a GLP-1 drug? Glucagon-like peptide 1 (GLP-1) weight-loss drugs such as Zepbound and Wegovy are growing in popularity. And that has made the companies who make those drugs, Eli Lilly and Novo Nordisk, hot investments over the past few years.
Why MariTide could have multiple advantages over other GLP-1 drugs
- MariTide, also known as AMG 133, is a GLP-1 injectable treatment that has shown comparable weight-loss results to existing drugs.
- MariTide requires less frequent injections, potentially making it more appealing to patients.
- The drug has demonstrated longer-lasting effects even after treatment cessation, addressing a key concern with other GLP-1 drugs.
The drug still has a long way to go
- While promising, MariTide is still in early trials and faces uncertainties regarding approval and revenue generation.
- Investors should closely monitor further trial results to assess the drug's potential market impact.
Should you invest in Amgen stock today? Discover the investment opportunities and potential returns associated with Amgen in light of MariTide's promising developments.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.